| Ytd | 274.11% | |
| 1y | 110.57% |
| Open | 15.05 | Prev Close | 14.94 | Low | 14.33 | High | 15.35 | Mkt Cap | 441.85M |
| Vol | 13.84K | Avg Vol | 108.61K | EPS | -0.28 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 10.20 | 200-d Avg | 5.78 | 1yr Est | 0.00 |
TTRX News
WBB Securities analyst Karen Sterling downgrades Turn Therapeutics (NASDAQ:TTRX) from Hold to Sel
Gainers Scinai Immunotherapeutics (NASDAQ:SCNI) shares rose 25.3% to $2.08 during Friday's afte
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's
In-vivo study showed GX-03 reduced IL-36, a key early driver of the inflammatory cascade, by approxi
Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a br
Clinically meaningful efficacy observed across a broader spectrum of atopic dermatitis supports expa
Turn Therapeutics, Inc. (NASDAQ:TTRX), a clinical-stage biotechnology company developing targeted, n
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70
Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the anal
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and m
Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analy
D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechn
Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock
Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges
Turn Therapeutics' shares surged 134% in after-hours trading following its Nasdaq debut, despite